Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
May 23, 2023
-
REGULATORY Ophthalmic Mitomycin, OD Tablets for Takecab and Tarlige to Get Listing on May 24
May 23, 2023
-
REGULATORY MHLW Cancels Expert Panel Meeting on May 23, Report Delayed
May 23, 2023
-
BUSINESS Sawai and Towa Profits Tank 50% on Flat Sales in Japan: FY2022 Earnings
May 22, 2023
-
BUSINESS Astellas CEO Confident about Veozah Uptake, 500 Billion Yen Sales Potential
May 22, 2023
-
ORGANIZATION Industry, Academia Groups Applaud Govt’s New Biosimilar Goal, but Fret Pricing, Biosame Issues
May 19, 2023
-
BUSINESS Qol to Further Expand Espha's AG Biz, Eyes Biosame Territory: Exec
May 19, 2023
-
BUSINESS Lecanemab’s Social Value in Japan Simulated at 4.7 Million Yen per Patient/Year: Eisai
May 18, 2023
-
REGULATORY Market Expansion Re-Pricing to Hit Tarlige, Entresto, Verzenio; Spillover to 2 Other Meds
May 18, 2023
-
REGULATORY Create Command Tower to Integrate Innovation Support and Drug Pricing Policy: LDP Project Chief
May 17, 2023
-
REGULATORY Chuikyo OKs Listing of Omvoh, Entyvio SC, Besremi, and More; Biggest Sales Outlook for Lilly Drug
May 17, 2023
-
REGULATORY Novo’s Obesity Drug Wegovy Skips May Listing, Sobi’s Empaveli Too
May 17, 2023
-
BUSINESS Daiichi Sankyo Set to Sharpen Focus on Innovation with Generic Divestment
May 17, 2023
-
BUSINESS Daiichi Sankyo to Divest Espha Generic Unit for 25 Billion Yen
May 16, 2023
-
BUSINESS 400 Staffers Pitching Leqembi in US, Tapping Digital Tools: Eisai CEO
May 16, 2023
-
BUSINESS FDA Approves Astellas’ Blockbuster Hopeful for Hot Flash Treatment
May 16, 2023
-
REGULATORY G7 Health Chiefs Vow to Spur Antibiotic and Dementia Drug Development, Access to Vaccines
May 15, 2023
-
BUSINESS Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
May 12, 2023
-
REGULATORY LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
-
BUSINESS Kyowa Kirin Axes Flagship Kidney Disease Drug Candidate
May 11, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…